| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present invention refers to compounds of formula 1a: n , wherein: A means CH=CH orS; R 23 means hydrogen, halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyloxy or (C 1 -C 4 )-alkyl-S-; R 24 means hydrogen or halogen when A means CH=CH or hydrogen, halogen, (C 1 -C 4 )-alkyl when A means S; X means N(H)C=O, N(H)S(O) 2 , C=ON(H) or S(O) 2 N(H); Y means C(R 12 )=C(R 13 ), N=C(R 14 ) or C(R 15 )=N, or condensed optionally substituted 5-7-member carbocyclyl; R 12 means hydrogen, halogen, (C 1 -C 10 )-alkyl, (C 2 -C 10 )-alkenyl, (C 3 -C 6 )-cycloalkyloxy, (C 3 -C 10 )-cycloalkenyloxy, (C 3 -C 6 )-cycloalkyl, (C 3 -C 10 )-cycloalkenyl, (C 3 -C 6 )-cycloalkyl[(C 1 -C 4 )-alkyl or (C 2 -C 4 )-alkenyl], (C 3 -C 6 )-cycloalkyl (C 1 -C 4 )-alkyloxy, (C 1 -C 10 )-alkyloxy, (C 3 -C 10 )-alkenyloxy, (C 1 -C 10 )-alkyl-S-, cyano, (C 1 -C 10 )-alkylcarbonyl- or phenyl; R 13 means hydrogen, halogen or (C 1 )-alkyl; R 14 means hydrogen or (C 1 -C 3 )-alkyl-S(O) m ; R 15 means hydrogen, halogen, (C 1 -C 10 )-alkyl, amino, [(C 1 -C 10 )-alkyl or (C 2 -C 10 )-alkenyl] amino, [(C 1 -C 10 )-alkyl or (C 2 -C 10 )-alkenyl]((C 1 -C 10 )-alkyl)amino or nitro; R 21 means hydrogen; R 22 means hydrogen, halogen, (C 1 )-alkyl, while Y means C(R 12 )=C(R 13 ), N=C(R 14 ) or C(R 15 )=N; R 51 means COOH or CONH(R 53 ); R 53 means R 55 -SO 2 - or tetrazolyl; R 55 means (C 1 -C 4 )-alkly; and m is equal to 0; wherein all specified phenyl groups may be independently substituted by one or more halogen atoms; wherein all specified alkyl groups may be independently substituted by one or more fluorine atoms; or its stereoisomer form, a mixture of stereoisomer forms in any ratio or its physiologically acceptable salt, provided the following compounds are excluded: 2-benzoylamino-2,3-dihydro-2-indencarboxylic acid; 2-(naphthalin-2-ylsulphonylamino)indane-2-carboxylic acid. Also, the invention refers to a pharmaceutical composition possessing CXCR5 receptor inhibitory activity on the basis of the compounds described above, as well as a method of treating a patient, involving introducing said compounds into the patient. n EFFECT: there are prepared and described the new compounds which possess CXCR5 inhibitory action and may be used for treating and preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, and Crohn's disease. n 17 cl, 397 ex |